AMENDMENT NO. 4 TO SCHEDULE TO
This Amendment No. 4 (this Amendment No. 4) amends and supplements the Tender Offer Statement on Schedule TO originally
filed by
Coca-Cola Consolidated, Inc., a Delaware corporation (Coca-Cola Consolidated or the Company), on May 20, 2024 (together with any amendments or supplements thereto, the Schedule TO) in connection
with the Companys offer to purchase for cash up to $2,000 million in value of shares of its issued and outstanding Common Stock, par value $1.00 per share, at a price of not less than $850 nor greater than $925 per share upon the terms
and subject to the conditions described in the Offer to Purchase, dated May 20, 2024 (the Offer to Purchase), a copy of which was filed as
Exhibit (a)(1)(A) to the Schedule TO, and in the related Letter of Transmittal (the
Letter of Transmittal), a copy of which was filed as
Exhibit (a)(1)(B) to the Schedule TO.
Only those items amended or
supplemented are reported in this Amendment No. 4. Except as specifically provided herein, the information contained in the Schedule TO remains unchanged and this Amendment No. 4 does not modify any of the information previously reported
on the Schedule TO. You should read this Amendment No. 4 together with the Schedule TO and all exhibits attached thereto, including the Offer to Purchase and the Letter of Transmittal, as each may be amended or supplemented from time to time
(the Offer).
Items 1 through 12.
The disclosure in the Offer to Purchase and Items 1 through 12 of the Schedule TO, to the extent such items incorporate by reference the
information contained in the Offer to Purchase, is hereby amended as follows:
|
|
|
The Company has entered into the Credit Agreements and completed its offering of $700,000,000 aggregate principal
amount of its 5.250% Notes due 2029 and $500,000,000 aggregate principal amount of its 5.450% Notes due 2034. The Company expects the proceeds from borrowings under the Credit Agreements and the offering of the Notes to be available to the Company
to purchase the shares of Common Stock accepted for payment pursuant to the Offer and, as a result, the Company has waived the Financing Condition. |
|
|
|
All references to the Financing Condition are hereby deleted in their entirety.
|
Item 7. Source and Amount of Funds or Other Consideration.
Item 7(a), (b) and (d) of the Schedule TO are hereby amended and supplemented by the following information:
We expect to fund the Offer and the Share Repurchase, including related fees and expenses, with a combination of cash on hand, borrowings under
the Revolving Credit Facility, borrowings under the Term Loan Facilities and/or proceeds from the offering of the Notes.
Entry into
the Term Loan Agreement and Revolving Credit Facility Agreement
On June 10, 2024, the Company entered into a term loan agreement
(the Term Loan Agreement) with Wells Fargo Bank, National Association (Wells Fargo), as administrative agent, and the other lenders party thereto, providing for a senior unsecured term loan facility in the aggregate principal
amount of up to $800 million, maturing on June 10, 2027 (the Three-Year Term Loan Facility), and a senior unsecured term loan facility in the aggregate principal amount of up to $500 million maturing on June 10, 2029
(the Five-Year Term Loan Facility and, together with the Three-Year Term Loan Facility, the Term Loan Facilities). Loans under the Term Loan Facilities may be requested by the Company on a delayed draw basis in one or more
advances on any business day from the period from June 10, 2024 through and including the earliest of (i) the date 90 days thereafter, (ii) the applicable maturity date and (iii) the applicable termination date (such period, the
Draw Period). Subject to obtaining commitments from lenders and satisfying other conditions specified therein, at the Companys option, additional incremental term loans may be established under the Term Loan Facilities to increase
the aggregate principal amount of term loans under the Term Loan Facilities by up to $500 million. The proceeds of the Term Loan Facilities, if drawn, may be used for general corporate purposes, which may include repurchases of the
Companys common stock, funding for working capital, payment of dividends and capital expenditures.